MedPath
HSA Approval

CATHEJELL LIGNOCAINE GEL 2% w/w

SIN15780P

CATHEJELL LIGNOCAINE GEL 2% w/w

CATHEJELL LIGNOCAINE GEL 2% w/w

August 15, 2019

PHARMAFORTE SINGAPORE PTE LTD

PHARMAFORTE SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMAFORTE SINGAPORE PTE LTD
Licence HolderPHARMAFORTE SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

GEL, JELLY

TOPICAL

Medical Information

N01BB02

lidocaine

Manufacturer Information

PHARMAFORTE SINGAPORE PTE LTD

Pharmazeutische Fabrik Montavit Ges.m.b.H.

Active Ingredients

LIGNOCAINE HYDROCHLORIDE MONOHYDRATE 2.33 g/100 g EQV LIGNOCAINE HYDROCHLORIDE

20 mg/g

Lidocaine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CATHEJELL LIGNOCAINE GEL 2% w/w - HSA Approval | MedPath